These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 9724486)
1. Implications of the diabetes control and complications trial for renal outcomes and medical nutrition therapy. Delahanty LM J Ren Nutr; 1998 Apr; 8(2):59-63. PubMed ID: 9724486 [TBL] [Abstract][Full Text] [Related]
2. Kidney disease and related findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. de Boer IH; Diabetes Care; 2014; 37(1):24-30. PubMed ID: 24356594 [TBL] [Abstract][Full Text] [Related]
3. The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial. Diabetes; 1996 Oct; 45(10):1289-98. PubMed ID: 8826962 [TBL] [Abstract][Full Text] [Related]
4. Clustering of long-term complications in families with diabetes in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group. Diabetes; 1997 Nov; 46(11):1829-39. PubMed ID: 9356033 [TBL] [Abstract][Full Text] [Related]
5. The Diabetes Control and Complications Trial (DCCT). Design and methodologic considerations for the feasibility phase. The DCCT Research Group. Diabetes; 1986 May; 35(5):530-45. PubMed ID: 2869996 [TBL] [Abstract][Full Text] [Related]
6. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes; 1995 Aug; 44(8):968-83. PubMed ID: 7622004 [TBL] [Abstract][Full Text] [Related]
7. Insights from the diabetes control and complications trial/epidemiology of diabetes interventions and complications study on the use of intensive glycemic treatment to reduce the risk of complications of type 1 diabetes. Genuth S Endocr Pract; 2006; 12 Suppl 1():34-41. PubMed ID: 16627378 [TBL] [Abstract][Full Text] [Related]
8. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group JAMA; 2002 May; 287(19):2563-9. PubMed ID: 12020338 [TBL] [Abstract][Full Text] [Related]
9. Effects of prior intensive versus conventional therapy and history of glycemia on cardiac function in type 1 diabetes in the DCCT/EDIC. Genuth SM; Backlund JY; Bayless M; Bluemke DA; Cleary PA; Crandall J; Lachin JM; Lima JA; Miao C; Turkbey EB; Diabetes; 2013 Oct; 62(10):3561-9. PubMed ID: 23520132 [TBL] [Abstract][Full Text] [Related]
10. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. ; Lachin JM; Genuth S; Cleary P; Davis MD; Nathan DM N Engl J Med; 2000 Feb; 342(6):381-9. PubMed ID: 10666428 [TBL] [Abstract][Full Text] [Related]
11. The effect of metabolic control on development and progression of diabetic nephropathy. Di Landro D; Catalano C; Lambertini D; Bordin V; Fabbian F; Naso A; Romagnoli GF Nephrol Dial Transplant; 1998; 13 Suppl 8():35-43. PubMed ID: 9870424 [TBL] [Abstract][Full Text] [Related]
12. Beneficial effects of intensive therapy of diabetes during adolescence: outcomes after the conclusion of the Diabetes Control and Complications Trial (DCCT). White NH; Cleary PA; Dahms W; Goldstein D; Malone J; Tamborlane WV; J Pediatr; 2001 Dec; 139(6):804-12. PubMed ID: 11743505 [TBL] [Abstract][Full Text] [Related]
13. Role of intensive glucose control in development of renal end points in type 2 diabetes mellitus: systematic review and meta-analysis intensive glucose control in type 2 diabetes. Coca SG; Ismail-Beigi F; Haq N; Krumholz HM; Parikh CR Arch Intern Med; 2012 May; 172(10):761-9. PubMed ID: 22636820 [TBL] [Abstract][Full Text] [Related]
14. Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. The Diabetes Control and Complications Trial Research Group. Ann Intern Med; 1998 Apr; 128(7):517-23. PubMed ID: 9518395 [TBL] [Abstract][Full Text] [Related]
15. Effects of Prior Intensive Insulin Therapy and Risk Factors on Patient-Reported Visual Function Outcomes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Cohort. ; Gubitosi-Klug RA; Sun W; Cleary PA; Braffett BH; Aiello LP; Das A; Tamborlane W; Klein R JAMA Ophthalmol; 2016 Feb; 134(2):137-45. PubMed ID: 26584339 [TBL] [Abstract][Full Text] [Related]
16. Good glycemic control remains crucial in prevention of late diabetic complications--the Linköping Diabetes Complications Study. Nordwall M; Arnqvist HJ; Bojestig M; Ludvigsson J Pediatr Diabetes; 2009 May; 10(3):168-76. PubMed ID: 19175900 [TBL] [Abstract][Full Text] [Related]
17. [Prevention and remission of diabetic nephropathy]. Sugimoto T; Nakamura Y; Makino H Nihon Rinsho; 2003 Jul; 61(7):1167-71. PubMed ID: 12877079 [TBL] [Abstract][Full Text] [Related]
18. Effect of glucose variability on the long-term risk of microvascular complications in type 1 diabetes. Kilpatrick ES; Rigby AS; Atkin SL Diabetes Care; 2009 Oct; 32(10):1901-3. PubMed ID: 19549736 [TBL] [Abstract][Full Text] [Related]
19. The relationship between glucose control and the development of diabetic nephropathy in type I diabetes. Molitch ME Semin Nephrol; 1997 Mar; 17(2):101-13. PubMed ID: 9148376 [TBL] [Abstract][Full Text] [Related]
20. Effect of prior intensive insulin treatment during the Diabetes Control and Complications Trial (DCCT) on peripheral neuropathy in type 1 diabetes during the Epidemiology of Diabetes Interventions and Complications (EDIC) Study. Albers JW; Herman WH; Pop-Busui R; Feldman EL; Martin CL; Cleary PA; Waberski BH; Lachin JM; Diabetes Care; 2010 May; 33(5):1090-6. PubMed ID: 20150297 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]